Silica-induced macrophage pyroptosis propels pulmonary fibrosis through coordinated activation of relaxin and osteoclast differentiation signaling to reprogram fibroblasts

Silica nanoparticle (SiNP) exposure induces severe pulmonary inflammation and fibrosis, but the pathogenesis remains unclear, and effective therapies are currently lacking. To explore the mechanism underlying SiNPsinduced pulmonary fibrosis, we constructed in vivo silica exposure animal models and in vitro models of silicainduced macrophage pyroptosis and fibroblast transdifferentiation. We found that SiNP exposure elicits upregulation of pulmonary proteins associated with pyroptosis, including NLRP3, ASC, IL-1 beta, and GSDMD, while the immunofluorescence staining co -localized NLRP3 and GSDMD with macrophage -specific biomarker F4/80 in silica -exposed lung tissues. However, the NLRP3 inhibitor MCC950 and classical anti -fibrosis drug pirfenidone (PFD) were found to be able to alleviate silica -induced collagen deposition in the lungs. In in vitro studies, we exposed the fibroblast to a conditioned medium from silica -induced pyroptotic macrophages and found enhanced expression of alpha-SMA, suggesting increased transdifferentiation of fibroblast to myofibroblast. In line with in vivo studies, the combined treatment of MCC950 and PFD was demonstrated to inhibit the expression of alpha-SMA and attenuate fibroblast transdifferentiation. Mechanistically, we adopted high throughput RNA sequencing on fibroblast with different treatments and found activated signaling of relaxin and osteoclast differentiation pathways, where the expression of the dysregulated genes in these two pathways was examined and found to be consistently altered both in vitro and in vivo. Collectively, our study demonstrates that SiNP exposure induces macrophage pyroptosis, which subsequently causes fibroblast transdifferentiation to myofibroblasts, in which the relaxin and osteoclast differentiation signaling pathways play crucial roles. These findings may provide valuable references for developing new therapies for pulmonary fibrosis.